IndustryCompany release

Biogen Q3 revenue rises 11% to $2.8bn on Apellis products; EPS guidance floor lifted

🇺🇸 Biogen Inc. (BIIB) · Wed 28 Oct 2026

Biogen reported a 49% jump in Growth Portfolio revenue, helped by SYFOVRE and EMPAVELI, and raised the low end of its 2026 non-GAAP EPS guidance.

Biogen reported third-quarter 2026 results on 28 October, with total revenue of $2.8bn, up 11%. Growth Portfolio revenue rose 49%, which the company linked in part to the first full quarter of contributions from the Apellis products SYFOVRE and EMPAVELI.

Biogen acquired Apellis in May 2026. The third quarter was therefore the first period in which both products were included for the whole three months.

On a GAAP basis, the company posted a loss of $0.14 per share. It attributed this to transaction-related charges, including $284m of acquired in-process research and development (IPR&D) expenses tied mainly to RayThera.

Biogen raised the low end of its 2026 non-GAAP EPS guidance, which now stands at $12.20 to $13.00. The company also said it expects multiple Phase 3 readouts over the next 12 months. The summary available to VigiEye did not name the programmes or give timings.

What it means for your team

  • Market-access teams should note that SYFOVRE and EMPAVELI are now part of Biogen's Growth Portfolio, which may affect the company's commercial priorities and payer engagement.
  • Regulatory teams may want to track the multiple Phase 3 readouts Biogen expects within 12 months, as these could lead to later filings. Specific programmes have not been identified in the material reviewed.
  • Acquired IPR&D charges, such as the $284m tied mainly to RayThera, explain the gap between GAAP and non-GAAP earnings this quarter.

Company's press release (SEC filing): Biogen Inc. ↗

Article written by VigiEye from the official source (Biogen Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →